News

The study is a randomized, double-blind, placebo-controlled study in approximately 140 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations

BioMarin Pharmaceutical has reported that its clinical trial application, or CTA, for BMN 110 or N-acetylgalactosamine 6-sulfatase, intended for the treatment of the lysosomal storage disorder mucopolysaccharidosis type

According to the company, the Therakos Cellex photopheresis system is an easy-to-use, integrated system that uses extracorporeal photopheresis, a cellular therapy, to relieve the symptoms of cutaneous T-cell

The new company, headquartered in Deerfield, Illinois, will focus on acquiring and operating specialty pharmaceutical companies and products. Target opportunities include products which are already approved or currently

ACell’s MatriStem regenerative medicine technology is a naturally occurring bioscaffold derived from porcine tissue. When MatriStem is placed onto a wound, it is resorbed and replaced with new

This study follows on positive outcomes in the Phase I study assessing the safety, pharmacokinetics and efficacy of the combination. The Phase II Advance trial will assess NPI-2358

Under the terms of the agreement Merck will pay Xencor an upfront license fee of $3 million, and an additional payment upon selection of an Xtend variant. Merck

This follows the expiry of the agreement between the two companies under which Wyeth has held the marketing authorization for Prostap (leuprorelin acetate) from Takeda in the UK

Most recently, Ms Barrett held the position of vice president and general manager of oncology business unit at Cephalon. Ms Barrett’s previous oncology experience also includes managing Johnson